Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Ashutosh Sureka
Ashutosh Sureka

Abbott Laboratories receives U.S. FDA authorization for Libre Duo system as stock edges lower

Abbott Laboratories receives U.S. FDA authorization for Libre Duo system as stock edges lower
Abbott Laboratories stock edges lower today

Abbott Laboratories has received U.S. FDA authorization for its Libre Duo 10 Day system, a first-of-its-kind, two-in-one biowearable designed for people living with diabetes. The stock edges lower on the day, trading at $116.16.

ABT price prediction
24H 0.42%
$106.65
48H 0.7%
$106.94
7D 0.33%
$106.55
1M 1%
$107.26
3M 1.28%
$107.56
6M -16.51%
$88.67
12M -21.15%
$83.74
Detailed
Current price: $106.2 1.64 1.56%
Closed 10/30
Daily range 105.41 Arrow from to Icon 106.73
Weekly range 101.70 Arrow from to Icon 106.73
Loading...

Highlights

  • Abbott Laboratories received FDA authorization for its Libre Duo 10 Day biowearable system for diabetes management.
  • Abbott Laboratories stock edges lower on the day, trading at $116.16.
  • 81 of 109 analysts rate Abbott Laboratories stock a buy, with a recent UBS price target of $125.

Abbott Laboratories has received U.S. FDA authorization for its Libre Duo 10 Day system, according to a post shared by AbbottNews. The Libre Duo 10 Day system is described as a first-of-its-kind, two-in-one biowearable. The post also points out that diabetic ketoacidosis is a serious health risk for people living with diabetes that can rapidly require hospitalization.

Bullish structure holds as gap down signals limited upside near resistance

A gap down at the open from $116.67 to $116.17 defines the session. Shares of Abbott Laboratories continue to trade above their MA-20, MA-50, and MA-200, maintaining a bullish daily structure even as the move runs counter to recent strength. The weekly high at $117.34 acts as the nearest resistance. RSI is elevated at 77.8, indicating stretched conditions that limit room for further upside.

Upside odds dominate as traders gauge reaction to weekly high

To gauge whether the recent move will gain traction, traders should monitor price action near the weekly high at $117.34. The session began with a gap down, opening at $116.17 compared with the prior close of $116.67. Even so, while the past week showed a sustained move lower with a firm trend, upside probability stands at 78% and downside at 22% for the coming trading week, with an expected range between $114.17 and $118.14. A close above $117.34 would confirm buyers are taking control, whereas a drop below $112.91 would suggest sellers are regaining momentum. On the weekly chart the longer-term picture stays constructive.

Earlier, analysts noted that Abbott Laboratories' shares remained technically strong, though overbought signals pointed to the risk of near-term consolidation. The current FDA authorization of the Libre Duo 10 Day system adds a new dimension to the story, and traders should watch for confirmation of direction if price breaks above $117.34 or falls below $112.91 in coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Can Bitcoin make you a millionaire?
  • By Pavlo Kot
  • 8 hours ago
Can Bitcoin make you a millionaire?
Editors' Picks
France's crypto market matures as regulation reshapes the industry
  • By Olena Litvinenko
  • Yesterday
France's crypto market matures as regulation reshapes the industry
Editors' Picks
SK Hynix’s rise reshapes the global chip industry and economy
  • By Dmytro Kharkov
  • Yesterday
SK Hynix’s rise reshapes the global chip industry and economy
Editors' Picks
All Editors' Top Picks

Latest Abbott News

Abbott stock holds range as neutral momentum signals point to continued consolidation: weekly analysis
  • By Ivan Andriyenko
  • 29.10.2026
Abbott stock holds range as neutral momentum signals point to continued consolidation: weekly analysis
Stocks
#Forecast #Abbott
Abbott Laboratories shares stall below resistance at $102.46 as momentum splits on MACD and Bull/Bear Power: weekly analysis
  • By Ashutosh Sureka
  • 22.10.2026
Abbott Laboratories shares stall below resistance at $102.46 as momentum splits on MACD and Bull/Bear Power: weekly analysis
Stocks
#Forecast #Abbott
Abbott Laboratories stock falls as sentiment turns cautious on weaker sales growth forecast
  • By Mykhailo Ihnatenko
  • 21.10.2026
Abbott Laboratories stock falls as sentiment turns cautious on weaker sales growth forecast
Stocks
#Forecast #Abbott
All Abbott News
  • Pavlo Kot
  • 8 hours ago
Can Bitcoin make you a millionaire?
  • Olena Litvinenko
  • Yesterday
France's crypto market matures as regulation reshapes the industry
  • Dmytro Kharkov
  • Yesterday
SK Hynix’s rise reshapes the global chip industry and economy
  • Eugene Komchuk
  • Yesterday
Binance hack: The biggest theft in crypto history
  • Ksenia Gerey
  • 29.10.2026
From PlayStation to crypto: Why Sony is building its own blockchain
  • Ksenia Gerey
  • 13 min ago
DTCC selects Canton for tokenization alongside major firms, Ran Neuner notes
  • Hanna Syniavska
  • 17 min ago
StarkWare develops Starknet and STARKs for Ethereum, Neil Jacobs notes
  • Daria Chernytska
  • 40 min ago
Richard Teng: 90% of stolen crypto assets replenished, Binance aims to cover remainder
  • Elena Nikulina
  • 41 min ago
Ryan Detrick: Experts discuss rates, Fed, and economy at Excell conference panel
  • Igor Krasulya
  • 43 min ago
Henri Arslanian: Bitcoin reaches 18th anniversary as milestone noted
Top News
  • Ivan Andriyenko
  • 12 min ago
Apple overtakes Nvidia as world's most valuable company with market cap above $5 trillion
Apple overtakes Nvidia as world's most valuable company with market cap above $5 trillion
  • Daria Chernytska
  • 31 min ago
Intel shares plunge 29% after earnings report in worst drop since 1974
Intel shares plunge 29% after earnings report in worst drop since 1974
  • Anastasiia Chabaniuk
  • 5 hours ago
Fitch cuts France's rating outlook to negative over deficit and debt risks
Fitch cuts France's rating outlook to negative over deficit and debt risks
  • Kyle Torpey
  • 6 hours ago
Trump says U.S. probes possible North Korean role in $6.3 billion Binance hack
Trump says U.S. probes possible North Korean role in $6.3 billion Binance hack
  • Pavlo Kot
  • 8 hours ago
Can Bitcoin make you a millionaire?
Can Bitcoin make you a millionaire?
Live News
  • Andrey Mastykin
  • Now
Eurozone economy slows as France slips into recession fears
  • Anton Kharitonov
  • Now
EUR/USD recovery stalls near 1.1210 as dollar retains its fundamental advantage
  • Anastasiia Chabaniuk
  • Now
Binance launches stolen asset recovery and allocates $6.34 billion to cover losses
  • Mykhailo Ihnatenko
  • Now
AMD stock drops over 7% as Intel outlook hits semiconductor sentiment
  • Jose Antonio Gastelum
  • Now
Circle phases out old USDC bridge as CCTP V2 takes over
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers